+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-acting DPP-4 Inhibitor Drug Market - Global Forecast 2025-2030- Product Image
Long-acting DPP-4 Inhibitor Drug Market - Global Forecast 2025-2030- Product Image
Sale

Long-acting DPP-4 Inhibitor Drug Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6140417
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global long-acting DPP-4 inhibitor market is undergoing notable transformation, with new technologies and regulatory pathways rapidly advancing therapeutic outcomes and market strategies. Senior leaders in pharmaceuticals, biotechnology, and healthcare will find actionable guidance for realizing product growth and preserving commercial viability amid complex supply, pricing, and policy frameworks.

Market Snapshot: Long-acting DPP-4 Inhibitors

Chronic diseases such as type 2 diabetes continue to drive demand for innovative therapies. Over the past decade, long-acting DPP-4 inhibitors have gained traction, with the market characterized by significant advances, evolving combination regimens, and a global shift toward patient-centric dosage forms. Robust specialty pharmacy networks, diversified sourcing strategies, and real-world evidence platforms are emerging as critical factors in market expansion. The current environment supports regulatory harmonization, accelerated product reviews, and high rates of patient uptake, particularly in regions prioritizing national health initiatives.

Scope & Segmentation of the Report

  • Dosage Forms: Focus on combination tablets, extended-release tablets, and traditional tablets, each catering to distinct patient needs and manufacturing challenges.
  • Distribution Channels: Breakout into hospital pharmacy, online pharmacy, and retail pharmacy, informing tailored engagement and education tactics.
  • Therapy Modes: Clear delineation between combination therapy and monotherapy, each with unique clinical positioning and payer dynamics.
  • Strength Variants: Coverage of 100mg, 50mg, and 25mg strengths enables titration and flexible dosing strategies.
  • End Users: Analysis across clinics, home care settings, and hospitals, emphasizing the value of specialty support programs.
  • Molecules: Examination of alogliptin, linagliptin, saxagliptin, sitagliptin, and vildagliptin, taking into account patent and competitive landscapes.
  • Regional Focus: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (e.g., United Kingdom, Germany, France, United Arab Emirates, South Africa), and Asia-Pacific (including China, India, Japan, Australia, Southeast Asia).
  • Key Companies: Insight into strategies and innovations of Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, AstraZeneca plc, and Novartis AG.

Key Takeaways for Leadership Teams

  • Long-acting DPP-4 inhibitor research benefits from advances in polymeric matrix technology and nanoparticle encapsulation, supporting once-weekly or extended-release formulations over traditional daily dosing.
  • Combination therapies pairing DPP-4 inhibitors with other glucose-modulating agents highlight a shift towards multidimensional disease management to address complex patient needs.
  • Accelerated regulatory approvals are being enabled by robust real-world safety and efficacy data, assisting rapid market entry for novel formulations in several leading jurisdictions.
  • Digital health tools—such as remote monitoring and mobile adherence apps—are being integrated into treatment protocols, driving more personalized patient engagement and improved persistence.
  • Strategic partnerships between pharmaceutical companies, technology providers, and contract development organizations are key to sustaining product innovation and geographic reach.
  • Molecule-specific dynamics impact competitive positioning, formulary placement, and lifecycle management, making differentiated strategies essential for portfolio expansion.

Tariff Impact and Supply Chain Resilience

The introduction of new United States tariffs in 2025 has significantly impacted the supply chain for long-acting DPP-4 inhibitors. Manufacturers reliant on imports now face higher costs, often passed onto contract formulators and healthcare payers. Resulting shifts include revised supplier agreements, increased domestic sourcing, volume-based rebates, and the adoption of strategic alliances with local manufacturers. Companies are also implementing digital platforms for real-time risk monitoring and diversifying raw-material sources to maintain supply stability and margin protection.

Methodology & Data Sources

This report draws from a rigorous, multi-faceted methodology encompassing secondary research from peer-reviewed journals, regulatory filings, and industry reports. Proprietary databases on prescription trends, as well as primary interviews with leading endocrinologists and supply chain executives, support nuanced insight into adoption and pricing barriers. All findings are validated by an independent quality-assurance team to ensure analytical rigor and actionable relevance.

Why This Report Matters for Strategic Decision-Makers

  • Enables informed investment and partnership strategies by providing detailed analysis of market segmentation, evolving therapy models, and commercialization frameworks.
  • Supports portfolio optimization and resilient supply planning through the integration of regulatory and tariff impact insights.
  • Empowers leadership with forward-looking recommendations tailored to ongoing healthcare system changes and competitive pressures.

Conclusion

Long-acting DPP-4 inhibitors are driving a new era of chronic disease management, shaped by advances in formulation science and digital integration. This report offers strategic guidance for capturing growth, enhancing patient outcomes, and achieving long-term market sustainability.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of once-monthly DPP-4 inhibitor injections to improve patient adherence
5.2. Competitive landscape intensifies as novel oral DPP-4 fixed-dose combinations enter phase III trials
5.3. Increasing focus on cardiovascular outcome studies for long-acting DPP-4 inhibitors in diabetic populations
5.4. Market expansion driven by emerging economies approving biosimilar long-acting DPP-4 inhibitors
5.5. Strategic partnerships between biopharma companies and contract manufacturers for scalable DPP-4 injectable formulations
5.6. Regulatory momentum from FDA and EMA designations accelerating approval pathways for ultra-long-acting DPP-4 treatments
5.7. Patient-centric digital monitoring integration with long-acting DPP-4 therapy to optimize glycemic control
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Long-acting DPP-4 Inhibitor Drug Market, by Dosage Form
8.1. Introduction
8.2. Combination Tablet
8.3. Extended Release Tablet
8.4. Tablet
9. Long-acting DPP-4 Inhibitor Drug Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Long-acting DPP-4 Inhibitor Drug Market, by Therapy Mode
10.1. Introduction
10.2. Combination Therapy
10.3. Monotherapy
11. Long-acting DPP-4 Inhibitor Drug Market, by Strength
11.1. Introduction
11.2. 100mg
11.3. 25mg
11.4. 50mg
12. Long-acting DPP-4 Inhibitor Drug Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Long-acting DPP-4 Inhibitor Drug Market, by Molecule
13.1. Introduction
13.2. Alogliptin
13.3. Linagliptin
13.4. Saxagliptin
13.5. Sitagliptin
13.6. Vildagliptin
14. Americas Long-acting DPP-4 Inhibitor Drug Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Takeda Pharmaceutical Company Limited
17.3.3. Boehringer Ingelheim International GmbH
17.3.4. AstraZeneca plc
17.3.5. Novartis AG
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. LONG-ACTING DPP-4 INHIBITOR DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. LONG-ACTING DPP-4 INHIBITOR DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. LONG-ACTING DPP-4 INHIBITOR DRUG MARKET: RESEARCHAI
FIGURE 28. LONG-ACTING DPP-4 INHIBITOR DRUG MARKET: RESEARCHSTATISTICS
FIGURE 29. LONG-ACTING DPP-4 INHIBITOR DRUG MARKET: RESEARCHCONTACTS
FIGURE 30. LONG-ACTING DPP-4 INHIBITOR DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COMBINATION TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COMBINATION TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY EXTENDED RELEASE TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY EXTENDED RELEASE TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY 100MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY 100MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY 25MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY 25MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY 50MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY 50MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY ALOGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY ALOGLIPTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY LINAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY LINAGLIPTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY SAXAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY SAXAGLIPTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY SITAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY SITAGLIPTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY VILDAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY VILDAGLIPTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 88. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 89. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 92. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 93. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 94. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 95. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 98. CANADA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 99. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 100. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 101. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 104. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 105. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 106. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 107. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 110. MEXICO LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 161. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 162. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 163. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 166. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 167. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 168. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 169. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 172. GERMANY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 173. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 174. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 175. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 178. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 179. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 180. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 181. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 184. FRANCE LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 197. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 198. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 199. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 202. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 203. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 204. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 205. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 208. ITALY LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 209. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 210. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 211. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 214. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 215. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 216. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 217. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 220. SPAIN LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 257. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 258. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 259. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 262. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 263. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 264. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 265. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 268. DENMARK LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 280. NETHERLANDS LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 281. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 282. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 283. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 286. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 287. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 288. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 289. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 292. QATAR LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 293. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 294. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 295. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 298. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 299. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 300. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 301. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 304. FINLAND LONG-ACTING DPP-4 INHIBITOR DRUG MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLIO

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Long-acting DPP-4 Inhibitor Drug market report include:
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International GmbH
  • AstraZeneca plc
  • Novartis AG

Related Topics

Related Reports

Type 2 Diabetes Mellitus Treatment Market - Global Forecast 2025-2030 - Product Image

Type 2 Diabetes Mellitus Treatment Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2025 - Product Image

Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030 - Product Image

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Type 2 Diabetes Medications Market - Global Forecast 2025-2030 - Product Image

Type 2 Diabetes Medications Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Antidiabetics Market Report 2025 - Product Image

Antidiabetics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.